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Following 28 days, coronary angiography was performed, animals
sacriﬁced and stented segments harvested for histopathological
evaluation.
RESULTS In angiography at 28 days, the late lumen loss was lowest in
the elevated dose SES (ed-frSES: 0.200.2 vs. frSES 0.800.5 vs. BMS:
0.960,50.5 mm, p<0,01). This was conﬁrmed in the morphometric
evaluation in histopathology as represented by signiﬁcant and dose
dependent decrease in percent area stenosis (ed-frSES: 22.412.7% vs.
frSES: 3510.7% vs. BMS: 47.512.5%; p<0,01). There was no peri-
strut inﬂammation in any of the groups. Endothelialisation score was
numerically, however not meaningfully decreased in ed-frSES (ed-
frSES: 2.93 vs. 3. vs. 3; p¼0,05). Signs of ﬁbrin were also noted in ed-
frSES (ed-frSES: 0,4 vs. frSES: 0 vs. BMS: 0, p¼0,05).
CONCLUSIONS Sirolimus dose dependent vascular response was re-
ported. The elevated dose, fast releasing SES shows satisfactory
vascular healing, similar to regular dose, fast release SES, with
improved efﬁcacy in restenosis inhibition.
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BACKGROUND Percutaneous coronary intervention (PCI) of coronary
calciﬁed lesions has been associated with worse clinical outcomes
compared to non-calciﬁed lesions. However, the impact of coronary
calciﬁcations (CC) two years after drug-eluting stent (DES) PCI is un-
known. We sought to evaluate the frequency and impact of CC two
years after DES PCI from the large ADAPT-DES registry.
METHODS ADAPT-DES was a prospective, multicenter “all-comers”
registry of consecutive patients successfully treated with at least one
DES. Two-year outcomes were analyzed according to the presence of
CC as assessed by the enrolling site operator.
RESULTS A total of 8,578 patients underwent DES PCI; CC of at least
one target lesion was present in 2,646 patients (30.8%). Patients with
CC were older, more frequently had diabetes, hypertension, dyslipi-
demia, renal insufﬁciency, left main or LAD disease, and multivessel
intervention, with more stents implanted. IVUS was used equally in
both groups. Second-generation DES were implanted less frequently
among patients with CC (60.5% vs. 64.7%, p¼0.0002). At two years,
CC patients had higher unadjusted rates of adverse ischemic and
bleeding events (Table). By multivariable analysis, the presence of CC
was a strong independent predictor of death (HR [95%CI] ¼ 4.92 [1.29,
18.80], myocardial infarction (HR [95%CI] ¼ 1.67 [1.26-2.23],p¼0.0004), MACE (HR [95%CI] ¼ 1.82 [1.37, 2.41], p<0.0001 and major
bleeding (HR [95%CI] ¼ 1.76 [1.44-2.16], p<0.0001).Calciﬁed lesions
(N[2,646)Non-calciﬁed lesions
(N[5,932) P-valueAll-cause death 4.8% (124) 3.5% (192) 0.003Cardiovascular 2.8% (73) 2.3% (124) 0.09Non-cardiovascular 2.0% (51) 1.2% (68) 0.008Myocardial infarction 6.4% (135) 4.0% (226) <0.0001ST deﬁnite/probable 1.2% (30) 1.1% (63) 0.82Any revascularization 21.7% (574) 19.7% (1167) 0.03Clinically-driven
TVR10.0% (264) 8.8% (525) 0.09Clinically-driven TLR 5.8% (153) 5.4% (322) 0.50Target vessel failure 18.2% (471) 14.2% (801) <0.0001MACE* 12.8% (329) 9.9% (556) <0.0001Major bleeding 14.0% (370) 6.2% (369) <0.0001Values are Kaplan-Meier estimates presented as % (n). TVR ¼ target vessel revascularization; ST ¼ stent
thrombosis; TLR ¼ target lesion revascularization; *MACE ¼ major adverse cardiovascular events, deﬁned as
the composite of cardiac death, myocardial infarction, or ischemia-driven target lesion revascularization;
target vessel failure ¼ the composite of cardiac death, target vessel revascularization, and MI.
CONCLUSIONS Target lesion CC as assessed by the interventionalist
is relatively frequent, being present in approximately one-third of
patients undergoing PCI. CCA was strongly predictive of adverse
ischemic and bleeding events 2 years after DES PCI.
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BACKGROUND Multiple coronary artery disease (CAD) including diabetic
patients (pts) remained a challenge for percutaneous coronary in-
terventions (PCI). Introduction of newer generation of drug eluting stent
(DES) signiﬁcantly improved safety and efﬁcacy compared with the pre-
vious ones although its value in pts with complex CAD in comparison with
1st generation DES is not established yet.
METHODS From March 2013 to February 2014, 225 pts with complex
CAD undergoing DES implantation in 15 centers in Argentina were
prospectively included. The registry was approved by local regula-
tory authorities and monitored by an independent safety committee.
Primary endpoint was to assess the incidence of major adverse car-
diovascular events (MACCE) deﬁned as death, myocardial infarction
(MI) stroke and unplanned new revascularization (TVR) using Fire-
bird-2 (2nd generation chromo-cobalt rapamycin eluting stent,
Microport Medical Co, Shanghai) vs. ERACI III population (DES arm)
at long term follow-up. Inclusion criteria were indication of
myocardial revascularization in 2, 3 major coronary arteries and/or
unprotected left main disease (ULMD). Exclusion criteria were poor
ejection fraction (<35%), recent ST elevation MI, previous DES,
lesion diameter < 2.5 mm, renal failure and contraindications for
dual antiplatelet therapy (DAPT). Stent thrombosis was analyzed. All
revascularization was done by intention-to-treat-principle and op-
erator’s advice was to treat only lesions  70% of diameter stenosis
in vessels with, at least, 2.0 mm of reference diameter, to fulﬁll a
modiﬁed in SYTNAX score. In ERACI IV the only DES allowed was
Firebird-2, whereas in ERACI III 1st DES generation was used. All
patients received DAPT for one year.
RESULTS Mean age of the 225 pts was 64.5 þ/- 11.0 years, with 30.6%
diabetics and 67.7% with 3 vessels or ULMD. Modiﬁed SYNTAX score
was 22 þ/- 11 and we implanted 1.7 þ/- 1.8 Firebird-2 per patient,
similar to the ERACI III DES arm (1.79), p¼0.8. Stent length was
41.4 mm þ/- 10.8 vs 36.1 mm þ/- 8.9 in ERACI IV and ERACI III,
B244 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5respectively (p<0.001). 20 þ/- 4 months of follow-up results are re-
ported in Table. In ERACI IV MACCE at 1 year was 2.2%, duplicating
this number up to 5.8% at 20 months, although compared to ERACI III,
ERACI IV has lower incidence of MACCE (p<0.001), the same outcome
was seen in diabetics (5.8% vs 25.5%, ERACI IV vs ERACI III respec-
tively, p<0.001) and non-diabetics (5.8% vs 12.4%, respectively p<
0.02)
Table20 months outcome ERACI III-DES ERACI IV-FRB2 p valueN patients 225 225 NADeath 7 (3.1%) 4 (1.8%) 0.54Acute myocardial
infarction (MI)10 (4.4%) 2 (0.9%) 0.01Non-fatal
cerebrovascular
accident (CVA)7 (3.1%) 0 (0.0%) 0.02Death/MI/CVA 21 (9.3%) 6 (2.7%) 0.003Unplanned
revascularization26 (11.6%) 8 (3.6%) 0.001MACCE 38 (16.9%) 13 (5.8%) <0.001Stent thrombosis
(ARC deﬁnition)7 (3.1%) 2 (0.9%) 0.17CONCLUSIONS At 20 þ/- 4 months this multicenter prospective reg-
istry showed that Firebird 2 stent used in complex lesions has a
remarkable low incidence of MACCE and other endpoints. Longer
follow-up is guaranteed to assess if these numbers remains over time.
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BACKGROUND The Svelte (New Providence, NJ) sirolimus-eluting
coronary stent utilizing a bioresorbable amino acid-based (PEA) drug
carrier is a novel stent-on-a-wire Integrated Delivery System (IDS)
consisting of a low-compliant balloon with balloon control bands
(BCBs) afﬁxed to a 0.014” integrated steerable wire with shapeable
tip. The IDS is low-proﬁle and speciﬁcally designed for use with the
transradial approach, ’slender’ PCI and direct stenting. The DIRECT I
ﬁrst-in-human study was designed to evaluate the feasibility of the
Svelte drug-eluting stent IDS.
METHODS Thirty patients with symptomatic ischemic heart disease
and a single de novo native coronary lesion suitable for percutaneous
coronary intervention were prospectively enrolled at 4 New Zealand
sites. Lesion length had to be <23 mm and the vessel reference
diameter 2.5-3.5 mm. The primary safety endpoint was 6-month target
vessel failure (TVF), deﬁned as the composite of death, target vessel
MI or clinically-driven target vessel revascularization (TLR). The pri-
mary efﬁcacy endpoint was 6-month angiographic in-stent late lumen
loss (LLL). All patients were scheduled to receive angiographic and
IVUS follow-up at baseline and 6-months, with 15 patients addition-
ally undergoing OCT analysis at the same time points. All angio-
graphic and clinical data were reviewed and adjudicated by an
independent core lab and DSMB at all reported time points.
RESULTS Twenty-nine of 30 enrolled patients completed 6-month
follow-up. Angiographic in-stent LLL was 0.22þ0.27 mm at 6-
months. Other 6-month follow-up included IVUS assessed neo-
intimal volume of 3.3þ 4.4mm3 and volume obstruction of 2.7þ4.5%.
OCT revealed 98þ4% strut coverage at a depth of 0.12þ0.06 mm.
Through 36-month followup, no patient has experienced stent
thrombosis, MACE or TVF.DIRECT First-In-Human Study 36-Mo. Follow-Up Patients (n[30)Device Success 29/30 (97%)All Death 0/30 (0%)All Myocardial Infarction 0/30 (0%)TLR, Clinically-Driven 0/30 (0%)TVR, Clinically-Driven 0/30 (0%)MACE 0/30 (0%)TVF, Angiographically-Driven 2/30 (7%)Stent Thrombosis, All Time Points 0/30 (0%)CONCLUSIONS This ﬁrst-in-human feasibility study demonstrated
minimal in-stent proliferation by angiography and conﬁrmed by IVUS,
along with near complete strut coverage by OCT. The concordant
excellent clinical outcomes, including no stent thrombosis, suggest
that the Svelte drug-eluting coronary stent IDS warrants further
evaluation. The novel approach to drug delivery may lessen the po-
tential side effects of impaired endothelial recovery, ﬁbrin deposition,
burst drug release and luminal stent strut drug residue sometimes
associated with durable polymer technologies, while direct stenting
with the IDS also minimizes procedural time and adjunctive product
use.
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BACKGROUND There are limited data on the clinical outcomes of
diabetic patients treated with bioresorbable scaffolds (BRS). The aim
of the present analysis is to compare the occurrence of clinical
events in diabetics treated with the Absorb bioresorbable vascular
scaffold (Absorb BVS; Abbott Vascular, Santa Clara, CA) versus
everolimus-eluting metal stents (EES; XIENCE; Abbott Vascular,
Santa Clara, CA).
METHODS The present study included 812 patients in the ABSORB
EXTEND study in which a total of 215 diabetic patients were treated
with Absorb BVS. In addition, 882 diabetic patients treated with EES
in pooled data from the SPIRIT clinical program (SPIRIT II [A Clinical
Evaluation of the XIENCE V Everolimus Eluting Coronary Stent Sys-
tem], SPIRIT III [Clinical Trial of the XIENCE V Everolimus Eluting
Coronary Stent System (EECSS)], SPIRIT IV Clinical Trial [Clinical
Evaluation of the XIENCE V Everolimus Eluting Coronary Stent Sys-
tem] and XIENCE V USA) were used for comparison by applying pro-
pensity score matching using 29 different variables (217 pairs).
The primary endpoint was major adverse cardiac events (MACE),
including cardiac death, myocardial infarction, and target lesion
revascularization.
RESULTS After propensity score matching, the baseline clinical
characteristics were similar in Absorb BVS and EES groups. As shown
in Figure 1 and Table 1, diabetic patients treated with the BRS had a
similar incidence of MACE compared with diabetics treated with EES
(5.7% vs. 5.6%, respectively; HR 0.99; 0.44-2.20; P¼0.98) after 393
days of follow-up.
